Idil Cavus

Idil Cavus, MD PhD has a diverse work experience in the field of neuroscience and clinical research. Idil has held various leadership roles and made significant contributions in both academia and the pharmaceutical industry.

Starting in 2001, Dr. Cavus worked at Yale University School of Medicine as an Assistant Professor in Psychiatry and Neurosurgery. During their time at Yale, they conducted translational research focusing on the role of glutamate, glutamine, and GABA in intractable seizures, cognition, energy metabolism, and neuronal plasticity. Idil also worked as an Attending Psychiatrist and an Associate Research Scientist in Molecular Psychiatry, where they studied the molecular and behavioral effects of estrogens and growth factors in rodent models of depression.

In 2008, Dr. Cavus joined Pfizer as the Director of the Specialty Business Unit in Neuroscience. Here, they served as the Global Clinical Lead for antipsychotic trials and was responsible for early and late drug development, translational studies, and regulatory submissions.

In 2011, Dr. Cavus moved to Bristol-Myers Squibb as the Group Director of Global Clinical Research in Neuroscience. In this role, they provided medical expertise for global clinical trials in various neurological disorders, including schizophrenia, major depression, neuropathic pain, Parkinson's, and Alzheimer's disease. Dr. Cavus also contributed to preclinical and translational medicine biomarker studies and provided clinical support for business development opportunities.

From 2013 to 2015, Dr. Cavus worked at Alexion Pharmaceuticals, Inc. as a Medical Director. Here, they gained expertise in clinical development for immunotherapy and orphan diseases, specifically Neuromyelitis Optica (NMO) and refractory Myasthenia Gravis (MG). Idil led pivotal Phase 3 trials in NMO, provided medical leadership throughout the clinical trial process, and collaborated with various stakeholders.

Since 2015, Dr. Cavus has been working at Worldwide Clinical Trials, initially as a Senior Medical Director, then as the Executive Director of CNS Therapeutic Area, and currently, as the Vice President and Neuroscience Therapeutic Area Lead. In their current role, they oversee the neuroscience therapeutic area and provides strategic direction for clinical trials.

Throughout their career, Dr. Cavus has collaborated on numerous research projects, grants, and publications. Idil has also been involved in teaching and lecturing, sharing their expertise in pharmacology and neuroscience with medical students and psychiatry residents.

In summary, Dr. Idil Cavus has made significant contributions to the field of neuroscience through their work in academia and the pharmaceutical industry. Idil'sexpertise in clinical research, drug development, and therapeutic areas make their a valuable asset in the field.

Dr. Idil Cavus holds an MD degree from Ege University, where they studied Medicine from 1982 to 1989. Idil also completed a Family Medicine Residency at Izmir Ataturk Hospital in Turkey from 1990 to 1991. Continuing their education, Dr. Cavus pursued a PhD in Neuroscience at Northeast Ohio Medical University (NEOMED) from 1991 to 1997. Following this, they completed a Psychiatry Residency with a Clinical Neuroscience Research Track at Yale University from 1997 to 2001. In 2004, Dr. Cavus obtained certification from the American Board of Neurology and Psychiatry.